Active Ingredient History
Albuterol is a short acting beta2-adrenergic receptor agonist. Albuterol effectively alleviates bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established. The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Asthma (approved 1996)
Airway Management (Phase 4)
Airway Obstruction (Phase 4)
Airway Remodeling (Phase 3)
Albuterol (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 2)
Anaphylaxis (Phase 4)
Anemia, Sickle Cell (Phase 1)
Asthma (Phase 4)
Asthma, Exercise-Induced (Phase 4)
Autonomic Nervous System Diseases (Phase 3)
Bipolar Disorder (Phase 3)
Brain Death (Phase 2)
Bronchial Spasm (Phase 3)
Bronchiolitis (Phase 4)
Bronchiolitis Obliterans (Phase 3)
Bronchiolitis, Viral (Phase 2)
Bronchitis (Phase 4)
Bronchoconstriction (Phase 4)
Bronchopulmonary Dysplasia (Phase 4)
Cannula (Phase 3)
Cesarean Section (Phase 4)
Cicatrix (Phase 1)
Ciliary Motility Disorders (Phase 1)
Conjunctivitis (Phase 3)
Cough (Phase 2)
Depressive Disorder, Major (Phase 1)
Diabetes Mellitus (Phase 1)
Diabetes Mellitus, Type 1 (Phase 1)
Drug Evaluation (Phase 2)
Dysautonomia, Familial (Phase 3)
Epinephrine (Phase 4)
Exercise (Phase 4)
Familial Primary Pulmonary Hypertension (Phase 2)
Fasting (Phase 1)
Food Hypersensitivity (Phase 4)
Glycogen Storage Disease Type II (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 4)
Heart Failure (Phase 3)
Heart Septal Defects, Ventricular (Phase 4)
Hyperkalemia (Phase 4)
Hypersensitivity (Phase 3)
Hypertension, Pulmonary (Early Phase 1)
Idiopathic Pulmonary Fibrosis (Phase 1)
Immune System Diseases (Early Phase 1)
Infant, Very Low Birth Weight (Phase 4)
Inflammation (Phase 4)
Inhalation (Phase 4)
Ligaments, Articular (Phase 1)
Lung Diseases (Phase 4)
Lung Diseases, Obstructive (Phase 4)
Lymphangioleiomyomatosis (Phase 2)
Memory Disorders (Phase 2)
Migraine Disorders (Phase 3)
Mucociliary Clearance (Phase 4)
Myasthenia Gravis (Phase 2/Phase 3)
Myasthenic Syndromes, Congenital (Phase 1)
Nausea (Phase 2)
Neuralgia, Postherpetic (Phase 3)
Organophosphate Poisoning (Phase 3)
Ozone (Phase 4)
Pain (Phase 3)
Pancreatitis (Phase 2)
Pediatric Obesity (Phase 4)
Pharmacokinetics (Phase 4)
Postural Balance (Phase 4)
Pulmonary Arterial Hypertension (Phase 3)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Pulmonary Edema (Phase 2)
Respiratory Distress Syndrome (Phase 2/Phase 3)
Respiratory Insufficiency (Phase 3)
Respiratory Sounds (Phase 4)
Respiratory Syncytial Virus Infections (Phase 4)
Rhinitis (Phase 3)
Rhinitis, Allergic, Seasonal (Phase 4)
Safety (Phase 2)
Sepsis (Phase 4)
Shock (Phase 4)
Signs and Symptoms, Respiratory (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Status Asthmaticus (Phase 4)
Tissue Donors (Phase 2)
Tobacco (Phase 4)
Tobacco Smoke Pollution (Phase 4)
Transient Tachypnea of the Newborn (Phase 1)
Venous Cutdown (Phase 4)
Ventilation (Phase 4)
Viruses (Phase 4)
Vomiting (Phase 3)
Water-Electrolyte Balance (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
